We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+11.08%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$134B
AUM Growth
+$14.8B
Cap. Flow
+$2.42B
Cap. Flow %
1.81%
Top 10 Hldgs %
25.29%
Holding
4,017
New
232
Increased
1,652
Reduced
1,816
Closed
191

Sector Composition

Rank Sector Weight
1 Technology 15.71%
2 Financials 9.02%
3 Healthcare 7.82%
4 Industrials 6.8%
5 Consumer Discretionary 5.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TE
3701
T1 Energy
TE
$1.53B
$48.9K ﹤0.01%
26,174
-1,000
-4% -$2.7K
SMR icon
3702
NuScale Power
SMR
$4.06B
$47.5K ﹤0.01%
14,442
-75,196
-84% -$267K
STEM icon
3703
PUT
Stem
STEM
$52.8M
$46.5K ﹤0.01%
465
-1,575
-77% -$109K
COMP icon
3704
Compass
COMP
$9.74B
$46.5K ﹤0.01%
12,363
+993
+9% +$2.45K
ADP icon
3705
PUT
Automatic Data Processing
ADP
$108B
$46K ﹤0.01%
+200
New +$46.6K
PIM
3706
Franklin Master Intermediate Income Trust
PIM
$153M
$45.3K ﹤0.01%
+14,211
New +$43.4K
VICI icon
3707
CALL
VICI Properties
VICI
$28.6B
$45K ﹤0.01%
+1,500
New +$44K
JMIA
3708
Jumia Technologies
JMIA
$720M
$44.8K ﹤0.01%
12,699
-5,286
-29% -$15.9K
EDF
3709
Virtus Stone Harbor Emerging Markets Income Fund
EDF
$170M
$44.6K ﹤0.01%
+10,343
New +$42.6K
MFV
3710
DELISTED
MFS SPECIAL VALUE TRUST
MFV
$44.5K ﹤0.01%
10,884
+99
+0.9% +$394
ETON icon
3711
Eton Pharmaceutcials
ETON
$1.15B
$44.2K ﹤0.01%
10,100
+100
+1% +$401
VICI icon
3712
PUT
VICI Properties
VICI
$28.6B
$44K ﹤0.01%
1,600
TPIC
3713
DELISTED
TPI Composites
TPIC
$43.3K ﹤0.01%
10,450
-4,037
-28% -$10.5K
PICK icon
3714
CALL
iShares MSCI Global Metals & Mining Producers ETF
PICK
$2.33B
$42.5K ﹤0.01%
+1,000
New +$39.8K
VNDA icon
3715
Vanda Pharmaceuticals
VNDA
$298M
$42.2K ﹤0.01%
+10,000
New +$40.3K
CMRX
3716
DELISTED
Chimerix, Inc.
CMRX
$41.6K ﹤0.01%
43,200
-6,000
-12% -$5.81K
SCYX icon
3717
SCYNEXIS
SCYX
$48.1M
$41.2K ﹤0.01%
2,312
BLDP
3718
Ballard Power Systems
BLDP
$784M
$40.3K ﹤0.01%
10,889
-1,065
-9% -$3.79K
CCLP
3719
DELISTED
CSI Compressco LP
CCLP
$39.6K ﹤0.01%
24,297
-4,918
-17% -$7.37K
THMO
3720
DELISTED
ThermoGenesis Holdings, Inc. Common Stock
THMO
$39.1K ﹤0.01%
65,004
PL icon
3721
Planet Labs
PL
$8.45B
$39.1K ﹤0.01%
15,813
-3,052
-16% -$7.22K
SLGC
3722
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$39K ﹤0.01%
15,400
-5,000
-25% -$11.6K
CMU
3723
DELISTED
MFS High Yield Municipal Trust
CMU
$37.8K ﹤0.01%
11,415
-15,000
-57% -$46.3K
SOAR icon
3724
Volato Group
SOAR
$8.51M
$37.8K ﹤0.01%
+400
New +$95K
AKBA icon
3725
Akebia Therapeutics
AKBA
$240M
$37.1K ﹤0.01%
29,917
+9,696
+48% +$9.89K

Similar funds

Raymond James & Associates's Q4 2023 Portfolio in Review

As of Q4 2023, Raymond James & Associates held 4,017 positions worth $134B, up 12% from $119B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Raymond James & Associates's Q4 2023 filing shows 232 new, 1,652 increased, 1,816 reduced and 191 closed positions. Its largest new stake was Delek US: 515,324 shares worth $13.3M. The largest sale was Pioneer Natural Resource Co., an estimated $124M.

By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 15% a quarter earlier, followed by Financials and Healthcare.

  • Raymond James & Associates's largest Q4 2023 buy was Delek US: 515,324 shares worth $13.3M.
  • Raymond James & Associates added most to State Street SPDR S&P 500 ETF Trust in Q4 2023, an estimated $219M increase.
  • Raymond James & Associates's biggest Q4 2023 reduction was Pioneer Natural Resource Co., cutting an estimated $124M.
  • Raymond James & Associates fully exited Kayne Anderson NextGen Energy & Infrastructure, Inc. in Q4 2023, selling an estimated $22.8M.
  • Raymond James & Associates's ten largest holdings make up 25% of its $134B portfolio in Q4 2023.
  • Raymond James & Associates opened 232 new positions and closed 191 in Q4 2023.
  • Raymond James & Associates's portfolio value rose 12% quarter-over-quarter to $134B.

Based on Raymond James & Associates's 13F filing for Q4 2023, filed 16 Jan 2024.